Polymer nanotherapeutics to correct autoimmunity

J Control Release. 2022 Mar:343:152-174. doi: 10.1016/j.jconrel.2021.12.036. Epub 2022 Jan 3.

Abstract

The immune system maintains homeostasis and protects the body from pathogens, mutated cells, and other harmful substances. When immune homeostasis is disrupted, excessive autoimmunity will lead to diseases. To inhibit the unexpected immune responses and reduce the impact of treatment on immunoprotective functions, polymer nanotherapeutics, such as nanomedicines, nanovaccines, and nanodecoys, were developed as part of an advanced strategy for precise immunomodulation. Nanomedicines transport cytotoxic drugs to target sites to reduce the occurrence of side effects and increase the stability and bioactivity of various immunomodulating agents, especially nucleic acids and cytokines. In addition, polymer nanomaterials carrying autoantigens used as nanovaccines can induce antigen-specific immune tolerance without interfering with protective immune responses. The precise immunomodulatory function of nanovaccines has broad prospects for the treatment of immune related-diseases. Besides, nanodecoys, which are designed to protect the body from various pathogenic substances by intravenous administration, are simple and relatively noninvasive treatments. Herein, we have discussed and predicted the application of polymer nanotherapeutics in the correction of autoimmunity, including treating autoimmune diseases, controlling hypersensitivity, and avoiding transplant rejection.

Keywords: Autoimmune disease; Hypersensitivity; Immunomodulation; Polymer nanotherapeutic; Transplant rejection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantigens
  • Autoimmune Diseases* / drug therapy
  • Autoimmunity*
  • Humans
  • Immune Tolerance
  • Polymers / pharmacology

Substances

  • Autoantigens
  • Polymers